<DOC>
	<DOCNO>NCT00026351</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Combining chemotherapy monoclonal antibody therapy may kill cancer cell . PURPOSE : Phase II trial study effectiveness combine pentostatin rituximab treat patient non-Hodgkin 's lymphoma chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Pentostatin Rituximab Treating Patients With Low-Grade Non-Hodgkin 's Lymphoma Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient low-grade B-cell non-Hodgkin 's lymphoma chronic lymphocytic leukemia treat pentostatin rituximab . - Determine duration response , median time progression , survival patient treat regimen . - Determine safety regimen patient . OUTLINE : This multicenter study . Patients receive rituximab IV alone day 1 course 1 . Patients receive rituximab IV pentostatin IV day 8 , 15 , 22 . An additional course drug administer day 36 , 43 , 50 . Patients progressive disease complete response receive treatment . Patients responsive disease , less complete response , receive one additional course therapy . Patients follow every 3 month . PROJECTED ACCRUAL : A total 50 non-Hodgkin 's lymphoma 50 chronic lymphocytic leukemia patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm lowgrade nonHodgkin 's lymphoma REAL classification : Bcell chronic lymphocytic leukemia Prolymphocytic leukemia Small lymphocytic lymphoma Follicular center lymphoma ( grade I , II , III ) Extranodal marginal zone Bcell lymphoma Malt type International Working Group classification : Small lymphocytic/chronic lymphocytic leukemia ( CLL ) CLL lymph node involvement allow Small lymphocytic plasmacytoid Follicular small cleave cell Follicular mix small large cell Follicular predominantly large cell Measurable disease Lymph node 1 cm long transverse diameter NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : More 6 month Hematopoietic : Absolute neutrophil count least 1,000/mm^3 Platelet count least 75,000/mm^3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 2.0 mg/dL AST great 5 time upper limit normal Renal : Creatinine le 2.0 mg/dL BUN normal Urinalysis normal Cardiovascular : LVEF normal patient history stable heart disease least 2 year Other : HIV negative No thyroid disease thyroid function maintain normal range No prior malignancy unless progression free 5 year Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Prior rituximab , Y2B8 , iodine I 131 tositumomab allow provide least 6 month elapse patient clear disease progression No concurrent immunotherapy Chemotherapy : No 6 prior chemotherapy drug No 3 prior treatment pentostatin At least 3 week since prior chemotherapy No prior cumulative lifetime dose 480 mg/m2 doxorubicin equivalent dose anthracycline No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No concurrent radiotherapy indicator lesion Surgery : Not specify Other : No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2002</verification_date>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
</DOC>